
Maxion Therapeutics raises $72m to advance KnotBody pipeline
Maxion Therapeutics has raised $72 million in an oversubscribed Series A Financing to advance its antibody-based KnotBody drugs for ion channel- and G protein coupled receptor (GPCR)-driven diseases. The financing was led by General Catalyst with additional investment from new investors, British Patient Capital, Solasta Ventures and Eli Lilly and… Read More
